HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

15.74 +0.38 (+2.47%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist

Price and Volume

Volume	31,650
Open	15.60
Bid (Size)	6.300 (100)
Ask (Size)	16.00 (500)
Prev. Close	15.36
Today's Range	15.60 - 15.79
52wk Range	12.98 - 19.50
Shares Outstanding	871,256,270
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

April 08, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

March 22, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Performance

YTD	+15.3%	+15.3%
1 Month	+11.8%	+11.8%
3 Month	-1.9%	-1.9%
6 Month	+4.0%	+4.0%
1 Year	+14.4%	+14.4%

More News

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

March 09, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

March 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Reports 2025 Full Year Results and Business Updates

March 05, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

March 04, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED to Announce 2025 Final Results

February 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

January 13, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

January 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

January 04, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

December 30, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

December 29, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

December 16, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

December 07, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

November 26, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

November 05, 2025

From Virtual Investor Conferences

Via GlobeNewswire

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®

November 04, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

November 02, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 31, 2025

From Virtual Investor Conferences

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 30, 2025

From Virtual Investor Conferences

Via GlobeNewswire

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

October 14, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

October 13, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

October 01, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday ↗

September 12, 2025

Via Benzinga

Frequently Asked Questions

Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?

Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.

What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?

HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?

The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market

What is the current price of HUTCHMED (China) Limited - American Depositary Shares?

The current price of HUTCHMED (China) Limited - American Depositary Shares is 15.74

When was HUTCHMED (China) Limited - American Depositary Shares last traded?

The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 04/17/26 04:00 PM ET

What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?

The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 13.71B

How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?

HUTCHMED (China) Limited - American Depositary Shares has 14B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.